Acurx Pharmaceuticals Inc (NASDAQ:ACXP) shares, rose in value on Wednesday, July 09, with the stock price up by 2.35% to the previous day’s close as strong demand from buyers drove the stock to $0.5.
Actively observing the price movement in the last trading, the stock closed the session at $0.49, falling within a range of $0.4804 and $0.5864. The value of beta (5-year monthly) was -1.372. Referring to stock’s 52-week performance, its high was $3.33, and the low was $0.30. On the whole, ACXP has fluctuated by 44.09% over the past month.
With the market capitalization of Acurx Pharmaceuticals Inc currently standing at about $11.74 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ACXP’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ACXP currently trading nearly 1.28% and 16.87% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.48, while the 7-day volatility ratio is showing 13.02% which for the 30-day chart, stands at 16.27%. Furthermore, Acurx Pharmaceuticals Inc (ACXP)’s beta value is -1.22.
A comparison of Acurx Pharmaceuticals Inc (ACXP) with its peers suggests the former has fared considerably weaker in the market. ACXP showed an intraday change of 2.35% in last session, and over the past year, it shrunk by -38.57%%.
Data on historical trading for Acurx Pharmaceuticals Inc (NASDAQ:ACXP) indicates that the trading volumes over the past 10 days have averaged 1.08 and over the past 3 months, they’ve averaged 6.26 million. According to company’s latest data on outstanding shares, there are 22.40 million shares outstanding.
Nearly 13.17% of Acurx Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 14.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.53 million shares as on 2025-06-13, resulting in a short ratio of 2.24. According to the data, the short interest in Acurx Pharmaceuticals Inc (ACXP) stood at 253.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 0.38 million. The stock has fallen by -75.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ACXP stock heading into the next quarter.
